Intrinsic value of CytomX Therapeutics - CTMX

Previous Close

$14.14

  Intrinsic Value

$11.03

stock screener

  Rating & Target

sell

-22%

Previous close

$14.14

 
Intrinsic value

$11.03

 
Up/down potential

-22%

 
Rating

sell

We calculate the intrinsic value of CTMX stock by summing up the current values of future distributable cash flows generated by the company and dividing the sum by the number of outstanding shares. As such, the intrinsic value calculation depends entirely on projections. The more accurate your projections of the company's performance are - the more reliable is the intrinsic value calculation result. Please make sure to check the stock valuation input data below and adjust it if necessary. The quality of the output (intrinsic valuation result) is only as good as the quality of the input. See also DISCLAIMERS.

STOCK VALUATION INPUT DATA

Revenue (in 0001), $M
Initial revenue growth rate, %
Terminal revenue growth rate, %
Revenue decline factor
Initial discount rate, %
Discount rate multiplier
Variable cost ratio, %
Fixed operating expenses, $M
Interest rate on debt, %
Effective corporate tax rate, %
Production assets / Revenue, %
Life of production assets, yrs
Working capital / Revenue, %
Revenue / Adjusted assets
Adjusted equity ratio
Cash flow adjustment, % of Revenue
Book value of equity, $M
Shares outstanding, mln
Market capitalization, $bln 0.6

 

FINANCIAL STATEMENTS FORECAST and PRESENT VALUE CALCULATION

Fiscal year
   2
   3
   4
   5
   6
   7
   8
   9
   10
   11
   12
   13
   14
   15
   16
   17
   18
   19
   20
   21
   22
   23
   24
   25
   26
   27
   28
   29
   30
   31

INCOME STATEMENT

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Revenue growth rate, %
  60.00
  54.50
  49.55
  45.10
  41.09
  37.48
  34.23
  31.31
  28.68
  26.31
  24.18
  22.26
  20.53
  18.98
  17.58
  16.32
  15.19
  14.17
  13.26
  12.43
  11.69
  11.02
  10.42
  9.87
  9.39
  8.95
  8.55
  8.20
  7.88
  7.59
Revenue, $m
  115
  177
  265
  384
  542
  745
  1,000
  1,313
  1,690
  2,135
  2,651
  3,241
  3,906
  4,648
  5,465
  6,357
  7,322
  8,360
  9,468
  10,645
  11,889
  13,199
  14,574
  16,013
  17,516
  19,084
  20,716
  22,415
  24,180
  26,016
Variable operating expenses, $m
  113
  174
  260
  378
  533
  732
  983
  1,291
  1,661
  2,097
  2,604
  3,184
  3,838
  4,566
  5,369
  6,245
  7,194
  8,213
  9,302
  10,458
  11,680
  12,967
  14,318
  15,732
  17,209
  18,749
  20,352
  22,021
  23,756
  25,559
Fixed operating expenses, $m
  62
  64
  65
  67
  68
  70
  71
  73
  74
  76
  77
  79
  81
  83
  85
  86
  88
  90
  92
  94
  96
  98
  101
  103
  105
  107
  110
  112
  115
  117
Total operating expenses, $m
  175
  238
  325
  445
  601
  802
  1,054
  1,364
  1,735
  2,173
  2,681
  3,263
  3,919
  4,649
  5,454
  6,331
  7,282
  8,303
  9,394
  10,552
  11,776
  13,065
  14,419
  15,835
  17,314
  18,856
  20,462
  22,133
  23,871
  25,676
Operating income, $m
  -61
  -61
  -61
  -60
  -59
  -57
  -54
  -50
  -45
  -39
  -31
  -22
  -12
  -1
  11
  25
  40
  57
  74
  93
  112
  133
  155
  178
  203
  228
  254
  282
  310
  340
EBITDA, $m
  -59
  -58
  -56
  -54
  -50
  -45
  -38
  -29
  -18
  -5
  10
  28
  49
  71
  97
  124
  155
  187
  222
  259
  298
  339
  383
  428
  476
  525
  577
  631
  687
  746
Interest expense (income), $m
  0
  0
  -11
  -8
  -3
  4
  13
  24
  39
  57
  78
  103
  132
  165
  203
  245
  291
  342
  396
  455
  517
  584
  654
  728
  806
  887
  972
  1,061
  1,153
  1,249
  1,349
Earnings before tax, $m
  -61
  -50
  -53
  -57
  -63
  -70
  -78
  -89
  -101
  -116
  -134
  -154
  -178
  -204
  -234
  -266
  -301
  -340
  -381
  -425
  -471
  -521
  -573
  -627
  -685
  -744
  -807
  -871
  -939
  -1,009
Tax expense, $m
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Net income, $m
  -61
  -50
  -53
  -57
  -63
  -70
  -78
  -89
  -101
  -116
  -134
  -154
  -178
  -204
  -234
  -266
  -301
  -340
  -381
  -425
  -471
  -521
  -573
  -627
  -685
  -744
  -807
  -871
  -939
  -1,009

BALANCE SHEET

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cash and short-term investments, $m
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Total assets, $m
  133
  206
  308
  447
  630
  866
  1,163
  1,527
  1,965
  2,482
  3,082
  3,768
  4,542
  5,404
  6,354
  7,392
  8,514
  9,721
  11,010
  12,378
  13,825
  15,348
  16,947
  18,620
  20,368
  22,191
  24,089
  26,063
  28,117
  30,251
Adjusted assets (=assets-cash), $m
  133
  206
  308
  447
  630
  866
  1,163
  1,527
  1,965
  2,482
  3,082
  3,768
  4,542
  5,404
  6,354
  7,392
  8,514
  9,721
  11,010
  12,378
  13,825
  15,348
  16,947
  18,620
  20,368
  22,191
  24,089
  26,063
  28,117
  30,251
Revenue / Adjusted assets
  0.865
  0.859
  0.860
  0.859
  0.860
  0.860
  0.860
  0.860
  0.860
  0.860
  0.860
  0.860
  0.860
  0.860
  0.860
  0.860
  0.860
  0.860
  0.860
  0.860
  0.860
  0.860
  0.860
  0.860
  0.860
  0.860
  0.860
  0.860
  0.860
  0.860
Average production assets, $m
  9
  14
  21
  30
  42
  58
  78
  102
  132
  166
  207
  253
  305
  363
  426
  496
  571
  652
  739
  830
  927
  1,030
  1,137
  1,249
  1,366
  1,489
  1,616
  1,748
  1,886
  2,029
Working capital, $m
  -76
  -117
  -175
  -254
  -358
  -493
  -661
  -868
  -1,117
  -1,411
  -1,752
  -2,142
  -2,582
  -3,072
  -3,612
  -4,202
  -4,840
  -5,526
  -6,259
  -7,036
  -7,859
  -8,725
  -9,633
  -10,585
  -11,578
  -12,614
  -13,693
  -14,816
  -15,983
  -17,197
Total debt, $m
  -208
  -142
  -51
  74
  239
  452
  719
  1,047
  1,441
  1,906
  2,446
  3,064
  3,760
  4,536
  5,391
  6,325
  7,335
  8,421
  9,581
  10,813
  12,115
  13,485
  14,924
  16,430
  18,003
  19,644
  21,352
  23,129
  24,977
  26,898
Total liabilities, $m
  120
  185
  277
  402
  567
  780
  1,047
  1,374
  1,769
  2,234
  2,774
  3,391
  4,088
  4,864
  5,719
  6,652
  7,663
  8,749
  9,909
  11,140
  12,442
  13,813
  15,252
  16,758
  18,331
  19,971
  21,680
  23,457
  25,305
  27,226
Total equity, $m
  13
  21
  31
  45
  63
  87
  116
  153
  197
  248
  308
  377
  454
  540
  635
  739
  851
  972
  1,101
  1,238
  1,382
  1,535
  1,695
  1,862
  2,037
  2,219
  2,409
  2,606
  2,812
  3,025
Total liabilities and equity, $m
  133
  206
  308
  447
  630
  867
  1,163
  1,527
  1,966
  2,482
  3,082
  3,768
  4,542
  5,404
  6,354
  7,391
  8,514
  9,721
  11,010
  12,378
  13,824
  15,348
  16,947
  18,620
  20,368
  22,190
  24,089
  26,063
  28,117
  30,251
Debt-to-equity ratio
  -15.600
  -6.920
  -1.650
  1.660
  3.800
  5.220
  6.180
  6.850
  7.330
  7.680
  7.940
  8.130
  8.280
  8.390
  8.480
  8.560
  8.620
  8.660
  8.700
  8.740
  8.760
  8.790
  8.810
  8.820
  8.840
  8.850
  8.860
  8.870
  8.880
  8.890
Adjusted equity ratio
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100

CASH FLOW

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Net income, $m
  -61
  -50
  -53
  -57
  -63
  -70
  -78
  -89
  -101
  -116
  -134
  -154
  -178
  -204
  -234
  -266
  -301
  -340
  -381
  -425
  -471
  -521
  -573
  -627
  -685
  -744
  -807
  -871
  -939
  -1,009
Depreciation, amort., depletion, $m
  2
  3
  4
  6
  9
  12
  16
  21
  27
  34
  41
  51
  61
  73
  85
  99
  114
  130
  148
  166
  185
  206
  227
  250
  273
  298
  323
  350
  377
  406
Funds from operations, $m
  -59
  -47
  -49
  -51
  -54
  -58
  -62
  -68
  -75
  -83
  -93
  -104
  -117
  -132
  -148
  -167
  -187
  -209
  -233
  -259
  -286
  -315
  -345
  -378
  -411
  -447
  -483
  -522
  -562
  -603
Change in working capital, $m
  -28
  -41
  -58
  -79
  -104
  -134
  -169
  -207
  -249
  -294
  -341
  -390
  -440
  -490
  -540
  -590
  -638
  -686
  -732
  -778
  -822
  -866
  -909
  -951
  -994
  -1,036
  -1,079
  -1,123
  -1,167
  -1,213
Cash from operations, $m
  -30
  -5
  9
  28
  50
  77
  106
  139
  174
  211
  249
  286
  323
  358
  392
  423
  451
  477
  500
  519
  536
  551
  563
  574
  582
  589
  595
  601
  606
  610
Maintenance CAPEX, $m
  -1
  -2
  -3
  -4
  -6
  -8
  -12
  -16
  -20
  -26
  -33
  -41
  -51
  -61
  -73
  -85
  -99
  -114
  -130
  -148
  -166
  -185
  -206
  -227
  -250
  -273
  -298
  -323
  -350
  -377
New CAPEX, $m
  -3
  -5
  -7
  -9
  -12
  -16
  -20
  -24
  -29
  -35
  -40
  -46
  -52
  -58
  -64
  -70
  -75
  -81
  -86
  -92
  -97
  -102
  -107
  -112
  -117
  -122
  -127
  -132
  -138
  -143
Cash from investing activities, $m
  -4
  -7
  -10
  -13
  -18
  -24
  -32
  -40
  -49
  -61
  -73
  -87
  -103
  -119
  -137
  -155
  -174
  -195
  -216
  -240
  -263
  -287
  -313
  -339
  -367
  -395
  -425
  -455
  -488
  -520
Free cash flow, $m
  -35
  -12
  0
  14
  32
  52
  75
  99
  124
  150
  175
  199
  221
  240
  256
  268
  277
  282
  283
  280
  273
  263
  250
  234
  215
  194
  170
  145
  118
  90
Issuance/(repayment) of debt, $m
  -208
  65
  92
  125
  165
  213
  267
  328
  394
  465
  540
  617
  696
  776
  855
  934
  1,011
  1,086
  1,160
  1,232
  1,302
  1,371
  1,439
  1,506
  1,573
  1,640
  1,708
  1,777
  1,848
  1,921
Issuance/(repurchase) of shares, $m
  318
  57
  63
  71
  81
  93
  108
  125
  145
  168
  194
  223
  255
  290
  329
  370
  414
  460
  510
  562
  616
  673
  733
  795
  859
  927
  996
  1,069
  1,144
  1,222
Cash from financing (excl. dividends), $m  
  110
  122
  155
  196
  246
  306
  375
  453
  539
  633
  734
  840
  951
  1,066
  1,184
  1,304
  1,425
  1,546
  1,670
  1,794
  1,918
  2,044
  2,172
  2,301
  2,432
  2,567
  2,704
  2,846
  2,992
  3,143
Total cash flow (excl. dividends), $m
  75
  110
  155
  211
  278
  358
  450
  552
  664
  783
  909
  1,039
  1,172
  1,306
  1,439
  1,571
  1,701
  1,828
  1,952
  2,073
  2,191
  2,307
  2,422
  2,535
  2,648
  2,761
  2,875
  2,991
  3,110
  3,233
Retained Cash Flow (-), $m
  -318
  -57
  -63
  -71
  -81
  -93
  -108
  -125
  -145
  -168
  -194
  -223
  -255
  -290
  -329
  -370
  -414
  -460
  -510
  -562
  -616
  -673
  -733
  -795
  -859
  -927
  -996
  -1,069
  -1,144
  -1,222
Prev. year cash balance distribution, $m
  314
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Cash flow adjustment, $m
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Cash available for distribution, $m
  71
  53
  92
  139
  197
  265
  342
  427
  519
  615
  715
  816
  917
  1,016
  1,111
  1,202
  1,287
  1,368
  1,442
  1,511
  1,575
  1,634
  1,689
  1,740
  1,788
  1,834
  1,879
  1,923
  1,966
  2,010
Discount rate, %
  4.30
  4.52
  4.74
  4.98
  5.23
  5.49
  5.76
  6.05
  6.35
  6.67
  7.00
  7.35
  7.72
  8.11
  8.51
  8.94
  9.39
  9.86
  10.35
  10.87
  11.41
  11.98
  12.58
  13.21
  13.87
  14.56
  15.29
  16.05
  16.86
  17.70
PV of cash for distribution, $m
  69
  49
  80
  115
  153
  192
  231
  267
  298
  323
  340
  348
  349
  341
  326
  305
  280
  252
  222
  192
  163
  136
  111
  89
  70
  54
  40
  30
  21
  15
Current shareholders' claim on cash, %
  50.0
  33.8
  25.1
  20.0
  16.6
  14.2
  12.5
  11.1
  10.1
  9.2
  8.4
  7.8
  7.3
  6.8
  6.3
  6.0
  5.6
  5.3
  5.0
  4.7
  4.5
  4.2
  4.0
  3.8
  3.6
  3.5
  3.3
  3.1
  3.0
  2.8

CytomX Therapeutics, Inc. is a clinical-stage, oncology-focused biopharmaceutical company. The Company uses its Probody technology platform to create cancer immunotherapies against clinically validated targets, as well as to develop cancer therapeutics against difficult-to-drug targets. Its pipeline is focused on the development of therapies in a set of modalities: Probody cancer immunotherapies, Probody drug conjugates, T-cell engaging Probody bispecifics and ProCAR-NK cell therapies. Its product candidates include CX-072, CX-2009, CX-2029, Cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) and CX-188. Its Probody platform utilizes active proteases in tumor tissue to allow monoclonal antibody-based therapies. Its investigational Probody therapeutics address clinically validated cancer targets in immuno-oncology, such as programmed death-ligand 1, against which CX-072 is directed, as well as targets, such as cluster of differentiation 166, against, which CX-2009 is directed.

FINANCIAL RATIOS  of  CytomX Therapeutics (CTMX)

Valuation Ratios
P/E Ratio -8.7
Price to Sales 34.4
Price to Book 6.6
Price to Tangible Book
Price to Cash Flow -258
Price to Free Cash Flow -129
Growth Rates
Sales Growth Rate 87.5%
Sales - 3 Yr. Growth Rate %
EPS Growth Rate %
EPS - 3 Yr. Growth Rate %
Capital Spending Gr. Rate 0%
Cap. Spend. - 3 Yr. Gr. Rate 14.9%
Financial Strength
Quick Ratio NaN
Current Ratio 0
LT Debt to Equity 0%
Total Debt to Equity 0%
Interest Coverage 0
Management Effectiveness
Return On Assets -29.8%
Ret/ On Assets - 3 Yr. Avg. -41.6%
Return On Total Capital -57.8%
Ret/ On T. Cap. - 3 Yr. Avg. -437.7%
Return On Equity -57.8%
Return On Equity - 3 Yr. Avg. 961.9%
Asset Turnover 0.1
Profitability Ratios
Gross Margin 0%
Gross Margin - 3 Yr. Avg. 0%
EBITDA Margin -380%
EBITDA Margin - 3 Yr. Avg. -461.7%
Operating Margin -400%
Oper. Margin - 3 Yr. Avg. -470.8%
Pre-Tax Margin -393.3%
Pre-Tax Margin - 3 Yr. Avg. -476.9%
Net Profit Margin -393.3%
Net Profit Margin - 3 Yr. Avg. -476.9%
Effective Tax Rate 0%
Eff/ Tax Rate - 3 Yr. Avg. 0%
Payout Ratio 0%

CTMX stock valuation input parameters

Revenue. Company's revenue (or sales) is always the starting point of any cash flow forecast. In the CTMX stock intrinsic value calculation we used $71.623 million for the last fiscal year's total revenue generated by CytomX Therapeutics. The default revenue input number comes from 0001 income statement of CytomX Therapeutics. You may change it if you feel that it should be adjusted for some unusual circumstances that are not expected to be repeated in the future or if you already know (from interim financial statements, for example) that this year's revenue is going to be quite different.

Revenue growth rate. Forecasted future revenue growth rate is the most important input parameter for the intrinsic value calculation. Unlike other input parameters that are reasonably expected to be in line with their historic averages or their historic trends, the revenue growth rate by and large is a wild card: nobody really knows what the company's revenue will be in the future. Of course, the level of unpredictability is different for different industries (utility companies being the most predictable and, thus, less risky).
    We use three input parameters to forecast the revenue growth rate in our CTMX stock valuation model: a) initial revenue growth rate of 60% whose default value is the revenue growth rate in the most recent quarter compared to the quarterly revenue a year ago; b) terminal revenue growth rate of 5% whose default value is chosen to be close to the average nominal (i.e. not adjusted for inflation) GDP growth rate; and c) revenue decline factor of 0.9, which stipulates that revenue growth rate in each forecasted year will be equal to the difference of the revenue growth rate in the preceding year and the terminal revenue growth rate multiplied by this revenue decline factor (with the passage of time the revenue growth rate will be approaching the terminal revenue growth rate, but not quite reaching it - though the difference could be infinitesimally small).
    At the revenue decline factor of 1, the future revenue growth rate is forecasted to be constant and equal to the initial revenue growth rate. The smaller the revenue decline factor, the faster the revenue growth rate will approach the terminal revenue growth.

Discount rate. The discount rate is used for determining the present value of future cash flows: future cash flows are "discounted" as at normal conditions (that translate into positive expected return on investment) one dollar today is worth more than the same dollar in the future. Unlike all other valuation models, we use variable discount rate, i.e. it increases for each consecutive year. This is done to account for higher risk of cash flows coming in further in the future.
    The initial discount rate of 4.3%, whose default value for CTMX is calculated based on our internal credit rating of CytomX Therapeutics, is applied to the cash flow expected to be received a year from now (well, actually, to be precise, in the financial year following the base year - the last year for which we have financial statements). For each consecutive year the discount rate is multiplied by the discount rate multiplier of 1.05, e.i. each year it increases by 5%. Feel free to change this number to correspond to your level of risk assessment of CytomX Therapeutics.
    By the way, it is easy to set the discount rate to be constant (this would make comparison with other valuation models easier): just set the discount rate multiplier equal to 1 and chose the magnitude of the initial discount rate to your liking.

Variable cost ratio is the ratio of variable costs (i.e. costs that fluctuate with fluctuation of the volume of production) to the revenue expressed as a percentage. In the calculation of intrinsic value of CTMX stock the variable cost ratio is equal to 98.6%.

Fixed operating expenses is just that - expenses that are not dependant on the volume of production. They are set to $61 million in the base year in the intrinsic value calculation for CTMX stock. These expenses increase with the level of inflation in subsequent years.

Interest rate on debt is the average all-in rate of interest paid by the company on its debt. It is set at 5.4% for CytomX Therapeutics.

Corporate tax rate of 27% is the nominal tax rate for CytomX Therapeutics. In reality, companies find ways to pay much less taxes than that or not to pay them at all.

Cash flow adjustment could be used for any adjustment the investor deems necessary. Most commonly we use this field to account for stock options-related effects in excess of what is reported on the company's income statement. The cash flow adjustment is expressed as a percentage of the revenue, and in the current valuation of the CTMX stock is equal to 0%.

Production assets are the company's assets used for manufacturing products or provision of services. In the valuation model input table they are expressed as a percentage of revenue and for CTMX are equal to 7.8%.

Life of production assets of 4.2 years is the average useful life of capital assets used in CytomX Therapeutics operations. It is used to calculate yearly capital expenditures needed to keep these assets in good order - we call it the maintenance CAPEX.

Working capital is the difference between the company's current assets and liabilities. In the model we use the ratio of working capital to revenue, which for CTMX is equal to -66.1%. A negative number means that the company is apt at using financial resources of its suppliers and customers; a large positive number, on the other hand, means that it either provides in-kind financing to others or is not good at managing its inventories.

Book value of equity - $69.896 million for CytomX Therapeutics - is used in calculation of the "floor" for intrinsic valuation based on the discounted cash flow (DCF) method. Even if the prospects are very bad for a company, its assets could always be sold now for their current fair market value.

Shares outstanding of 44.06 million for CytomX Therapeutics is needed to calculate the intrinsic value of one share.

Market capitalization is used here only for reference purposes and as a quick check that the share price and the number of shares outstanding numbers are correct - something especially to be cognizant about at stock splits. So, the market capitalization of CytomX Therapeutics at the current share price and the inputted number of shares is $0.6 billion.

RELATED COMPANIES Price Int.Val. Rating
BMY Bristol-Myers 53.27 71.64  hold
PFE Pfizer 43.21 34.10  hold
SGEN Seattle Geneti 54.39 1.07  str.sell
BLUE bluebird bio 122.78 7.95  str.sell
BLCM Bellicum Pharm 4.49 1.25  str.sell
NK NantKwest 2.31 0.69  str.sell

COMPANY NEWS

▶ CytomX Therapeutics: 3Q Earnings Snapshot   [04:58PM  Associated Press]
▶ CytomX to Present at Upcoming Healthcare Conferences   [Sep-25-18 08:00AM  GlobeNewswire]
▶ CytomX Therapeutics: 2Q Earnings Snapshot   [07:11PM  Associated Press]
▶ A guide to biotechs building boom in South City   [Jul-26-18 03:47PM  American City Business Journals]
▶ With new attack on Alzheimer's, this young biotech is hiring, grabbing more space   [Jul-23-18 03:05PM  American City Business Journals]
▶ CytomX Therapeutics: 1Q Earnings Snapshot   [May-09-18 06:13PM  Associated Press]
▶ CytomX Therapeutics beats Street 4Q forecasts   [05:01AM  Associated Press]
▶ CytomX to Present at Upcoming Investor Conferences   [Mar-01-18 04:05PM  GlobeNewswire]
▶ A Look into Amgens Collaborations in 2H17   [Jan-18-18 10:30AM  Market Realist]
▶ [$$] 5 Biotech Stocks a Pro Is Buying   [05:35AM  Barrons.com]
▶ CytomX Therapeutics Added to NASDAQ Biotechnology Index   [Dec-18-17 08:00AM  GlobeNewswire]
▶ CytomX Therapeutics reports 3Q loss   [Nov-07-17 07:03PM  Associated Press]
▶ CytomX Breaks Out On Mash-Up With Amgen In Immuno-Oncology   [Oct-04-17 04:25PM  Investor's Business Daily]
▶ CytomX stock rockets 35% after deal with Amgen   [Oct-03-17 05:07PM  MarketWatch]
▶ CytomX Therapeutics reports 2Q loss   [Aug-07-17 11:10PM  Associated Press]
▶ CytomX Announces Management Team Changes   [May-15-17 04:01PM  GlobeNewswire]
▶ CytomX Therapeutics reports 1Q loss   [May-05-17 08:14AM  Associated Press]

CONTACT US       ASSET ALLOCATION

About X-FIN       Site news       Privacy policy       Terms of use       FAQ

Copyright © X-FIN.com 2005-2018. All rigths reserved.